Literature DB >> 14603092

Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity?

Manya Magnus1, Rebecca Clark, Leann Myers, Thomas Farley, Patricia J Kissinger.   

Abstract

BACKGROUND AND OBJECTIVES: Trichomonas vaginalis (Tv) is a common sexually transmitted disease (STD) among HIV-infected populations. The relationship between Tv and immune status and HIV viral load as affected by protease inhibitor (PI) use has not been well examined. GOAL: The goals were to evaluate the association between Tv and both immune status and PI use among HIV-infected women, and to characterize factors associated with Tv among HIV-infected women. STUDY
DESIGN: We used a retrospective cohort study conducted between 1990 and 2000.
RESULTS: Of 1578 women, the majority was under 35 years, black (AA), and infected heterosexually or with unidentified risk. Thirty percent (30.2%) had Tv at least once, and 36.9% had at least one subsequent positive test; Tv was more common than chlamydia, gonorrhea, genital warts, or syphilis. After adjusting for follow-up time, young age, AA race, substance use, and other sexually transmitted diseases (STDs) were associated with initial Tv infection, but pregnancy, immune status, and PI use were not associated. After adjusting for follow-up time, having other STDs was associated with and pregnancy was protective of subsequent Tv positivity, but immune status and PI use were not associated; neither were age, race, or substance use.
CONCLUSION: Tv is a common STD among HIV-infected women and does not appear to be associated with immune status or PI use. Aggressive screening might represent a means of reducing the incidence and prevalence of Tv.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14603092     DOI: 10.1097/01.OLQ.0000086609.95617.8D

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  30 in total

1.  The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women.

Authors:  Megan Gatski; David H Martin; Judy Levison; Leandro Mena; Rebecca A Clark; Mary Murphy; Harold Henderson; Norine Schmidt; Patricia Kissinger
Journal:  Sex Transm Infect       Date:  2011-01-29       Impact factor: 3.519

2.  Patient-delivered partner treatment and Trichomonas vaginalis repeat infection among human immunodeficiency virus-infected women.

Authors:  Megan Gatski; Leandro Mena; Judy Levison; Rebecca A Clark; Harold Henderson; Norine Schmidt; Susan L Rosenthal; David H Martin; Patricia Kissinger
Journal:  Sex Transm Dis       Date:  2010-08       Impact factor: 2.830

3.  A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

4.  A Trich-y question: should Trichomonas vaginalis infection be reportable?

Authors:  Brooke E Hoots; Thomas A Peterman; Elizabeth A Torrone; Hillard Weinstock; Elissa Meites; Gail A Bolan
Journal:  Sex Transm Dis       Date:  2013-02       Impact factor: 2.830

Review 5.  Single-Dose Compared With Multidose Metronidazole for the Treatment of Trichomoniasis in Women: A Meta-Analysis.

Authors:  Katharine Howe; Patricia J Kissinger
Journal:  Sex Transm Dis       Date:  2017-01       Impact factor: 2.830

6.  Epidemiology and treatment of trichomoniasis.

Authors:  Patricia Kissinger
Journal:  Curr Infect Dis Rep       Date:  2015-06       Impact factor: 3.725

7.  Performance of a new, rapid assay for detection of Trichomonas vaginalis.

Authors:  Ann Kurth; William L H Whittington; Matthew R Golden; Katherine K Thomas; King K Holmes; Jane R Schwebke
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

8.  A prospective cohort study comparing the effect of single-dose 2 g metronidazole on Trichomonas vaginalis infection in HIV-seropositive versus HIV-seronegative women.

Authors:  Jennifer E Balkus; Barbra A Richardson; Vernon Mochache; Vrasha Chohan; Jeannie D Chan; Linnet Masese; Juma Shafi; Jeanne Marrazzo; Carey Farquhar; R Scott McClelland
Journal:  Sex Transm Dis       Date:  2013-06       Impact factor: 2.830

9.  Does Antiretroviral Therapy Interfere With the Treatment of Trichomonas vaginalis Among HIV+ Women?

Authors:  Patricia Kissinger; Alys Adamski; Rebecca A Clark; Leandro Mena; Judy Levison; David H Martin
Journal:  Sex Transm Dis       Date:  2013-06       Impact factor: 2.830

10.  Prevalence of sexually transmitted infections in HIV-1 infected pregnant women in Europe.

Authors:  Megan Landes; Claire Thorne; Patricia Barlow; Simona Fiore; Ruslan Malyuta; Pasquale Martinelli; Svetlana Posokhova; Valeria Savasi; Igor Semenenko; Andrej Stelmah; Cecilia Tibaldi; Marie-Louise Newell
Journal:  Eur J Epidemiol       Date:  2007-10-10       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.